Akoya Biosciences, INC Form 4 insider transactions

Quanterix Corporation's proposed acquisition of Akoya Biosciences has cleared the Hart-Scott-Rodino Antitrust Improvement Act waiting period, moving the merger closer to completion.

Akoya Biosciences and Quanterix announce the expiration of the Hart-Scott-Rodino Act waiting period, marking progress in their proposed merger expected to close in the second quarter of 2025.

Quanterix Corporation announces its proposed acquisition of Akoya Biosciences, aiming to expand its market reach into immunology and oncology while accelerating growth and profitability.

Akoya Biosciences and Quanterix are merging to combine their technologies, aiming to create a comprehensive solution for biomarker discovery from tissue to blood.

Quanterix's CEO presented at the J.P. Morgan Healthcare Conference, outlining the pending merger with Akoya Biosciences and its anticipated benefits, including significant cost synergies and revenue growth.

Akoya Biosciences and Quanterix are merging to create a fully integrated biomarker discovery and diagnostics solution, expected to close in the second quarter of this year.

Quanterix reports preliminary Q4 2024 revenue of $34.9 million and full year 2024 revenue of $137.2 million, representing 12% year-over-year growth for the full year, and discusses the pending acquisition of Akoya Biosciences.

Quanterix is set to acquire Akoya Biosciences in a stock-for-stock transaction aimed at creating a leader in biomarker detection across blood and tissue.

Akoya Biosciences and Quanterix Corporation are merging in an all-stock transaction to create a combined entity with a fully integrated technology ecosystem for biomarker discovery and diagnostics.

Quanterix will acquire Akoya Biosciences in an all-stock transaction, creating the first integrated solution for ultra-sensitive detection of bloodand tissue-based protein biomarkers.

Quanterix will acquire Akoya Biosciences in an all-stock transaction, creating the first integrated solution for ultra-sensitive detection of bloodand tissue-based protein biomarkers.

Akoya Biosciences' Chief Legal Officer, Jennifer Kamocsay, acquired 87,500 shares of common stock through the vesting of restricted stock units.

Akoya Biosciences CFO, John Frederick Ek, acquired 87,500 shares of common stock and reports holding 268,228 shares directly and 20,000 shares indirectly through a trust.

Pascal Bamford, Chief Clinical Officer of Akoya Biosciences, acquired 87,500 shares of common stock on November 19, 2024, through the vesting of restricted stock units.

Akoya Biosciences' Chief Business Officer, Niro Ramachandran, acquired 87,500 shares of common stock through the vesting of restricted stock units.

Akoya Biosciences CEO Brian McKelligon acquired 218,750 shares of common stock through the vesting of restricted stock units.

Director Scott Mendel acquired 44,959 stock options in Akoya Biosciences on October 2, 2024, according to a Form 4 filing.

Pascal Bamford, Chief Clinical Officer of Akoya Biosciences, acquired 40,000 restricted stock units on August 29, 2024.

Akoya Biosciences' CEO, Brian McKelligon, exercised stock options and sold 7,500 shares of common stock under a pre-arranged 10b5-1 trading plan.

Akoya Biosciences CEO Brian McKelligon exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Director Thomas A. Raffin acquired 50,000 stock options in Akoya Biosciences, Inc. on June 4, 2024, according to a Form 4 filing with the SEC.

Robert G. Shepler, a director of Akoya Biosciences, Inc., acquired 50,000 stock options at an exercise price of $2.01 on June 4, 2024, which will vest on June 4, 2025, or the next annual meeting.

Director Matthew Winkler acquired 50,000 stock options in Akoya Biosciences, Inc. on June 4, 2024.

Director Thomas P. Schnettler acquired 50,000 stock options in Akoya Biosciences, Inc. on June 4, 2024.

Myla Lai-Goldman, a director of Akoya Biosciences, acquired stock options for 50,000 shares on June 4, 2024.

Director Scott Mendel acquired 50,000 stock options in Akoya Biosciences, Inc. on June 4, 2024, subject to continuous service through the vesting date.

CFO of Akoya Biosciences, John Frederick Ek, reports disposition of shares to cover taxes on a restricted stock unit award.

Frederic Pla, Chief Operating Officer of Akoya Biosciences, reported a transaction involving the withholding of shares to cover taxes on a previously granted restricted stock unit award.

Niro Ramachandran, Chief Business Officer of Akoya Biosciences, reports the disposal of shares to cover taxes related to a restricted stock unit award.

Brian McKelligon, CEO of Akoya Biosciences, disposed of 7,135 shares of common stock on March 23, 2024, to cover taxes related to a previously granted restricted stock unit award.